Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Israel / NCT00722228
Recruiting Phase 1/2

Autologous and Allogeneic Whole Cell Cancer Vaccine for Metastatic Tumors

NCT00722228 · tracked via the Priya Life Science Israel tracker
Sponsor
Hadassah Medical Organization
Phase
Phase 1/2
Started
2008-07
Last updated
2025-10-02

Condition(s) studied

Colorectal CancerOvarian CancerGastric CancerBreast CancerLung CancerKidney CancerMelanoma

Investigational drug(s) / intervention(s)

Autologous or Allogeneic tumor cells

Autologous or Allogeneic tumor cells: Five vaccine doses, injected subcutaneously at 3-week intervals. Each dose is composed of irradiated and DNP-conjugated tumor cells.

Study summary

This study is based on the finding that tumor cells that are grown in the laboratory can be modified in such a way that, when injected to the patient, they will stimulate his/her immune response. This approach will be evaluated in patients with melanoma and colorectal, gastric, ovarian, breast, lung and kidney epithelial cancer. Tumor cells grown in the laboratory will be modified to make them stimulatory to the immune system, irradiated to kill them, and injected to the patient eight times at two-week intervals. This protocol is expected to prolong survival of metastatic cancer patients.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * One of the following metastatic cancers: Melanoma, breast, ovary, colorectal, gastric, lung or kidney * Above 18 years of age * Failure of at least one chemotherapy protocol * Clinical performance status of ECOG 0,1 * Absolute neutrophil count greater than 1000/mm3 * Serum ALT/AST less than three times the upper limit of normal * Serum creatinine less than or equal to 1.6 mg/dl. * Must be able to understand and sign the Informed Consent document Exclusion Criteria: * Below 18 years of age * Women who are pregnant * Life expectancy of less than three months

Trial sites (1)

FacilityCityRegionStatus
Hadassah Medical Organization Jerusalem Israel Recruiting

More Hadassah Medical Organization trials in Israel

Dipyridamole for Early-Onset Preeclampsia: A Pilot Study of Feasibility, Pharmacokinetics, and Biological Effects Starting soon
The Computerized Retraining and Functional Treatment - Group Intervention Recruiting
Testis Needle Aspiration of Sperm in Men With Azoospermia Recruiting
Vaginal Microbiome Transplantation for Recurrent Bacterial Vaginosis Active, not recruiting
Obstetric Risk Assessment & Cesarean-delivery in Labor Estimation Using Artificial Intelligence Recruiting

Other trials for the same condition

Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors Recruiting
CDK 4/6 Inhibitor, Ribociclib, With Adjuvant Endocrine Therapy for ER-positive Breast Cancer Active, not recruiting
Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib Active, not recruiting
Niraparib + Dostarlimab In BRCA Mutated Breast Cancer Active, not recruiting
A Phase II Study Of Nivolumab/ Bevacizumab/Rucaparib Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT00722228 on ClinicalTrials.gov ↗ ← All trials in Israel